Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford BioMedica CEO To Hire More People, Expects More Deals Following Gene Therapy Pact With Axovant

Executive Summary

Britain's Oxford BioMedica has signed a $842m deal with US-based Axovant Sciences to commercialize its next generation gene therapy for Parkinson's disease.

You may also be interested in...



Axovant Closes Chapter On Failed, Second-Rate Small Molecule Strategy

Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.

Biopharma Quarterly Dealmaking Statistics, Q2 2018

Biopharma financing for the second quarter totaled $12.4 billion, a 25% decrease from Q1 2018. Meanwhile Q2 merger and acquisition deal value reached $101 billion, three-quarters of which came from Takeda's $79 billion takeover of major European player Shire. Alliances – totaling $13.8 billion (a significant decline from the previous quarter's $30.7 billion) – featured large partnerships in the antibody space, the biotechnology industry sector with the highest dollar volume.

Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge

Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1130096

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel